Mao Lina, Yuanying Yuana, Jongyuan Xua et al.
[Abstract] In this trial, nasopharyngeal cancer stem cells (CSCs) were separated and cultured to produce a vaccine;its safety and efficacy were prospectively evaluated in low-, medium-, and high-dose groups. BetweenApril and September 2014, we enrolled 90 patients who met the enrolment criteria, and assigned them tothree groups (n = 30). Throughout the trial, injection site reaction was the most common reaction (81%),and fever was least common (31%); however, there was no difference among the three groups. Whenthe immune responses pre- and post-vaccination were compared, we found that the CSC-specific and-nonspecific response in the medium- and high-dose groups were both significantly enhanced. This studyis the first clinical trial of a nasopharyngeal CSC vaccine and preliminarily proves its safety and efficacy.
[Key words] Cancer stem cel; lVaccine; Nasopharyngeal cancer; Safety; Efficacy; Immunotherapy; Cancer preventiona
15nasopharyngeal cancer stem cell vaccine.pdf